Few individuals have shaped the myeloproliferative neoplasm (MPN) field as steadily and thoughtfully as Dr. Richard T. Silver, MD, FACP, whose career exemplified the power of patience, independence, and long‑term scientific commitment. Over decades, he helped move the field forward by asking difficult questions early, standing by promising science long before it gained consensus, and contributing to standards of research, care, and collaboration… Read More »Honoring Dr. Richard T Silver, MD

“A category 1 designation from the NCCN is not just a footnote change — it’s a signal flare,” said Dr. Aaron Gerds, MD, a hematologist, clinical investigator in MPNs, and Chair of the NCCN Myeloproliferative Neoplasms Panel. “It tells clinicians, patients, and payers that the data have matured to the point where this is no… Read More »NCCN updates guidance on interferon in essential thrombocythemia

In the clinic with a young MPN patient  A young adult sits across from Dr. Linda Resar, hands clasped, voice unsteady. The diagnosis is a mouthful — a myeloproliferative neoplasm (MPN) — and feels impossible. As Resar explains, “They go to the internet and they say, ‘Wow, I have cancer! I’m so young! This has to be devastating.’”   She slows the… Read More »Research spotlight: Dr. Linda Resar